LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

BioMarin Pharmaceutical Inc

Chiusa

SettoreSettore sanitario

56.61 2.46

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

55.09

Massimo

57.59

Metriche Chiave

By Trading Economics

Entrata

61M

186M

Vendite

-2.2M

745M

P/E

Media del settore

21.13

51.198

EPS

1.13

Margine di Profitto

24.919

Dipendenti

3,040

EBITDA

28M

224M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+76.23% upside

Dividendi

By Dow Jones

Utili prossimi

4 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-1.3B

11B

Apertura precedente

54.15

Chiusura precedente

56.61

Notizie sul Sentiment di mercato

By Acuity

50%

50%

166 / 380 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

BioMarin Pharmaceutical Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

10 giu 2024, 17:41 UTC

I principali Market Mover

Texas Pacific Land, Altair Engineering Hit 52-Week Highs on S&P MidCap 400 Inclusion

21 ago 2024, 11:30 UTC

Notizie principali

S&P 500 Futures Up In Premarket Trading; Target, Keysight Technologies Lead

Confronto tra pari

Modifica del prezzo

BioMarin Pharmaceutical Inc Previsione

Obiettivo di Prezzo

By TipRanks

76.23% in crescita

Previsioni per 12 mesi

Media 97.4 USD  76.23%

Alto 126 USD

Basso 70 USD

Basato su 18 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per BioMarin Pharmaceutical Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

18 ratings

14

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

59.405 / 62.19Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Very Strong Bearish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

166 / 380 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.